Additionally, the 36-month beta value for NVCR is 0.72. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for NVCR is 97.35M and currently, short sellers hold a 5.33% ratio of that float. The average trading volume of NVCR on December 27, 2024 was 1.32M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NVCR) stock’s latest price update
The stock of NovoCure Ltd (NASDAQ: NVCR) has increased by 3.00 when compared to last closing price of 30.97.Despite this, the company has seen a gain of 1.14% in its stock price over the last five trading days. fool.com reported 2024-12-06 that Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn’t grab hold of the stock fast enough. This momentum was helped by price target increases from analysts.
NVCR’s Market Performance
NovoCure Ltd (NVCR) has experienced a 1.14% rise in stock performance for the past week, with a 69.86% rise in the past month, and a 103.83% rise in the past quarter. The volatility ratio for the week is 4.96%, and the volatility levels for the past 30 days are at 8.30% for NVCR. The simple moving average for the past 20 days is 8.73% for NVCR’s stock, with a 72.41% simple moving average for the past 200 days.
Analysts’ Opinion of NVCR
Many brokerage firms have already submitted their reports for NVCR stocks, with Evercore ISI repeating the rating for NVCR by listing it as a “Outperform.” The predicted price for NVCR in the upcoming period, according to Evercore ISI is $30 based on the research report published on December 02, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NVCR reach a price target of $30, previously predicting the price at $24. The rating they have provided for NVCR stocks is “Buy” according to the report published on October 16th, 2024.
JP Morgan gave a rating of “Neutral” to NVCR, setting the target price at $15 in the report published on November 20th of the previous year.
NVCR Trading at 45.55% from the 50-Day Moving Average
After a stumble in the market that brought NVCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.53% of loss for the given period.
Volatility was left at 8.30%, however, over the last 30 days, the volatility rate increased by 4.96%, as shares surge +78.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +79.42% upper at present.
During the last 5 trading sessions, NVCR rose by +1.14%, which changed the moving average for the period of 200-days by +108.63% in comparison to the 20-day moving average, which settled at $29.34. In addition, NovoCure Ltd saw 113.66% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVCR starting from Paravasthu Mukund, who sale 44 shares at the price of $16.69 back on Nov 02 ’24. After this action, Paravasthu Mukund now owns 3,459 shares of NovoCure Ltd, valued at $734 using the latest closing price.
Puri Michal Nath, the Chief Human Resources Officer of NovoCure Ltd, sale 810 shares at $15.79 during a trade that took place back on Oct 31 ’24, which means that Puri Michal Nath is holding 110,093 shares at $12,792 based on the most recent closing price.
Stock Fundamentals for NVCR
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.76 for the gross margin
The net margin for NovoCure Ltd stands at -0.26. The total capital return value is set at -0.33. Equity return is now at value -39.70, with -12.65 for asset returns.
Based on NovoCure Ltd (NVCR), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.06. The debt to equity ratio resting at 1.81. The interest coverage ratio of the stock is -17.33.
Currently, EBITDA for the company is -175.87 million with net debt to EBITDA at -3.69. When we switch over and look at the enterprise to sales, we see a ratio of 6.82. The receivables turnover for the company is 8.62for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.49.
Conclusion
In conclusion, NovoCure Ltd (NVCR) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
